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Incidence and epidemiology
Gastrointestinal stromal tumours (GISTs) are rare tumours, with
an estimated unadjusted incidence of around 1/100 000/year [1].
This only covers clinically relevant GISTs, since, if investigated,
a much higher number of lesions 1 cm in diameter (microGISTs)
can be found at histopathological examination of stomach tissue in
middle-aged and elderly individuals.
There is a slight prevalence in males. The median age is around
60–65 years, with a wide range. Occurrence in children is very
VC The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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rare. Paediatric GIST represents a clinically and molecularly dis-
tinct subset, marked by female predominance, absence ofKIT/pla-
telet-derived growth factor alpha (PDGFRA) mutations, frequent
mutations or silencing of the four genes that encode the subunits
of the succinate dehydrogenase (SDH) enzyme complex, gastric
multicentric location and possible lymph node metastases [2].
Some syndromes are linked to GISTs:
• The Carney triad syndrome, marked by gastric GISTs, para-
ganglioma and pulmonary chondromas (these may occur at
different ages) [3];
• Carney–Stratakis syndrome, marked by a dyad of GIST and
paraganglioma [4, 5]; and
• Neuroﬁbromatosis type 1(NF1), possibly leading to wild-type
(WT), often multicentric GIST, predominantly located in the
small bowel [6].
Families with germline autosomal dominant mutations of KIT
are an extremely rare finding, presenting with multiple GISTs at
an early age, possibly along with other associated features such as
pigmented skin macules, urticaria pigmentosa and diffuse hyper-
plasia of the interstitial cells of Cajal in the gut wall.
Diagnosis and pathology/molecular biology
When small oesophagogastric or duodenal nodules< 2 cm in size
are detected, endoscopic biopsy may be difficult and laparo-
scopic/laparotomic excision may be the only way to make a histo-
logical diagnosis. Many of these small nodules, if diagnosed as
GISTs, will be either low-risk or entities whose clinical signi-
ficance remains unclear. Therefore, the standard approach to
patients with oesophagogastric or duodenal nodules < 2 cm is
endoscopic ultrasound assessment and then follow-up, reserving
excision for patients whose tumour increases in size or becomes
symptomatic [IV, C]. As an option, the patient can choose to
undergo a histological assessment, also depending on age, life
expectancy and comorbidities. If follow-up is the choice, an
evidence-based, optimal surveillance policy is lacking. A logical
approach may be to have a short-term first control (e.g. at
3 months) and then, in the case of no evidence of growth, a more
relaxed follow-up schedule may be selected.
In a histologically proven small GIST, standard treatment is exci-
sion, unless major morbidity is expected. Alternatively, in the case
of a likely low-risk GIST on biopsy, the decision can be made with
the patient to follow up the lesion. However, an exception is the
standard approach to rectal nodules represented by biopsy or exci-
sion after endorectal ultrasound assessment and pelvic magnetic
resonance imaging (MRI), regardless of the tumour size and
mitotic rate. In fact, the progression risk of a clinically significant
GIST at this site is higher, its prognosis is significantly worse com-
pared with most gastric GISTs and the local implications for sur-
gery are more critical. A follow-up policy may be an option, to be
discussed with the patient, in the case of small lesions and when-
ever the surgical risk is particularly high (comorbidities, age, etc.).
The standard approach to tumours 2 cm in size is biopsy/
excision, because they are associated with a higher risk of progres-
sion if confirmed as GIST [IV, C]. If there is an abdominal nodule
not amenable to endoscopic assessment, laparoscopic/laparo-
tomic excision is the standard approach. If there is a mass,
especially if surgery is likely to be a multivisceral resection, multi-
ple core needle biopsies are the standard approach. They should
be obtained through endoscopic ultrasound guidance, or
through an ultrasound/computed tomography (CT)-guided per-
cutaneous approach. This may allow the surgeon to plan the best
approach according to the histological diagnosis and avoid sur-
gery for diseases which might not benefit (e.g. lymphomas, mes-
enteric fibromatosis and germ cell tumours). The risk of
peritoneal contamination is negligible if the procedure is prop-
erly carried out. Moreover, lesions at risk in this regard (e.g. cystic
masses) should be biopsied only in specialised centres.
Immediate laparoscopic/laparotomic excision is an option on an
individualised basis, especially if surgery is limited. If a patient
presents with obvious metastatic disease, a biopsy of the meta-
static focus is sufficient and the patient usually does not require a
laparotomy for diagnostic purposes. The tumour sample should
be fixed in 4% buffered formalin (Bouin fixative should not be
used, since it prevents molecular analysis).
Pathologically, the diagnosis of GIST relies on morphology
and immunohistochemistry, the latter being positive for CD117
(KIT) and/or DOG1 (see Table 1) [7, 8]. A proportion of GISTs
(in the range of 5%) are CD117-negative. The mitotic count has a
prognostic value and should be expressed as the number of mito-
ses on a total area of 5 mm2 [which replaces the former 50 high-
power field (HPF) area]. Mutational analysis for known muta-
tions involving KIT and PDGFRA can confirm the diagnosis of
GIST, if doubtful (particularly in rare CD117/DOG1-negative
suspect GIST). Mutational analysis has a predictive value for sen-
sitivity to molecular-targeted therapy and to prognostic value. Its
inclusion in the diagnostic work-up of all GISTs should be con-
sidered standard practice [II, A] (with the possible exclusion of
< 2 cm non-rectal GISTs, which are very unlikely ever to be can-
didates for medical treatment). Centralisation of mutational
analysis in a laboratory enrolled in an external quality assurance
programme and with expertise in the disease may be useful.
Centralised pathological diagnosis is more strongly recom-
mended for KIT/PDGFRA WT GIST, to confirm the diagnosis of
GIST with an expert pathologist at a reference centre. In KIT/
PDGFRA/BRAF WT GIST, immunohistochemistry for SDHB is
done to identify SDH-deficient GIST. In quadruple-negative
GIST (KIT/PDGFRA/BRAF/SDH), an unrecognised underlying
NF1 syndrome should be excluded [9]. The collection of fresh
frozen tissue is encouraged, to allow new molecular pathology
assessments to be made at a later stage. Informed consent for
tumour storage (adhering to local and international guidelines)
should be sought, enabling later analyses and research.
Multidisciplinary treatment planning is needed, involving pathol-
ogists, radiologists, surgeons and, medical oncologists, as well as gas-
troenterologists, nuclear medicine specialists, etc., as applicable.
Management should be carried out in reference centres for sarcomas
and GISTs and/or within reference networks sharing multidiscipli-
nary expertise and treating a high number of patients annually.
Staging and risk assessment
The revised Union for International Cancer Control tumour,
node and metastasis classification of malignant tumours (UICC
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TNM 8), incorporates the main prognostic factors in GIST (see
Table 2) [10].
Prognostic factors are the mitotic rate, tumour size and
tumour site (gastric GISTs have a better prognosis than small
bowel or rectal GISTs). Tumour rupture is an additional adverse
prognostic factor and should be recorded, regardless of whether
it took place before or during surgery. Mutational status has not
been incorporated in any risk classification at present, although
some genotypes have a distinct natural history and, above all,
KIT/PDGFRA WT GISTs have peculiar clinical presentations and
course. Localised GIST with PDGFR D842V mutation are gener-
ally associated with a good prognosis and resistance to imatinib.
Several risk classifications have been proposed. A widely used
risk classification was proposed by the Armed Forces Institute of
Pathology, which incorporates the primary mitotic count,
tumour size and tumour site, i.e. the three main prognostic fac-
tors in localised GISTs [11, 12]. A nomogram utilising all three
criteria has been developed on another series [13]. When using
these tools, it is important to appreciate that the mitotic index
and tumour size are non-linear, continuous variables, so that
thresholds are interpreted wisely. Prognostic contour maps were
generated through a pool of series of GIST patients not treated
with adjuvant therapy, which incorporate the mitotic index and
tumour size as continuous non-linear variables, while tumour
rupture is considered in addition to tumour site [14]. They have
been validated against a reference series.
Staging procedures consider that most relapses affect the perito-
neum and the liver. Contrast-enhanced abdominal and pelvic CT
scan is the investigation of choice for staging and follow-up. MRI
may be an alternative. For rectal GISTs, MRI provides better pre-
operative staging information. Chest CT scan and routine labora-
tory testing complement the staging work-up of the
asymptomatic patient. The evaluation of fluorodeoxyglucose
(FDG) uptake using an FDG-positron emission tomography
(PET) scan, or FDG-PET–CT/MRI, is useful mainly when early
detection of the tumour response to molecular-targeted therapy is
of special interest.
Management of local/locoregional disease
(see Figure 1)
The standard treatment of localised GISTs is complete surgical
excision of the lesion, with no dissection of clinically negative
lymph nodes [III, A]. If laparoscopic excision is planned, the
technique needs to follow the principles of oncological surgery
[III, A] [15]. A laparoscopic approach is clearly discouraged in
patients who have large tumours, because of the risk of tumour
rupture, which is associated with a very high risk of relapse. R0
excision is the goal (i.e. an excision whose margins are clear of
tumour cells). When R0 surgery implies major functional seque-
lae, and preoperative medical treatment is not effective, the deci-
sion can be made with the patient to accept possible R1
(microscopically positive) margins [IV, B]. This is even more
acceptable for low-risk lesions, given the lack of any formal dem-
onstration that R1 surgery is associated with a worse overall
Table 1. Personalised medicine synopsis table
Biomarker Method Use LoE GoR
Mitotic
index
Pathology Disease classiﬁcation
Prognostic relevance
Used for medical treatment
decisions
IV A
KIT/PDGFRA/
BRAF
Sanger
sequencing
or NGS
Disease classiﬁcation
Prognostic relevance
Predictive relevance
Used for medical treatment
decisions
Currently actionable/
targetable
I A
SDH IHC Disease classiﬁcation
Prognostic relevance
Predictive relevance
Used for medical treatment
decisions
III A
GoR, grade of recommendation; IHC, immunohistochemistry; LoE, level
of evidence; NGS, next generation sequencing; PDGFRA, platelet-derived
growth factor receptor alpha; SDH, succinate dehydrogenase.
Table 2. Prognostic factors for GIST UICC TNM 8 (modiﬁed from [10])
Prognostic
factors
Tumour related Host
related
Environment
related
Essential Anatomical site
Histological type
Size of tumour
Depth of invasion
Grade (well to poorly
differentiated)
M category
Mitotic rate
Additional Presence of KIT mutation
Mutational site in KIT
or PDGFRA gene
Surgical resection margins
Presentation status
(primary versus recurrence)
NF1
Age
Quality of
surgery
New and
promising
TP53
Ki-67
Tumour hypoxia
GIST, gastrointestinal stromal tumour; NF1, neuroﬁbromatosis type 1;
PDGFRA, platelet-derived growth factor alpha; TNM, tumour, node,
metastasis; TP53, tumour protein 53; UICC, Union for International Cancer
Control.
Modiﬁed from [10] with permission from John Wiley & Sons, Inc.
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survival (OS). If R1 excision was already carried out, re-excision
may be an option, provided the original site of lesion can be
found, and major functional sequelae are not foreseen.
The risk of relapse can be substantial, as defined by available
risk classifications. Adjuvant treatment with imatinib for 3 years
was associated with a relapse-free survival (RFS) and OS advant-
age in comparison with 1 year of therapy in high-risk patients in a
randomised trial [16]. Previously, a placebo-controlled trial dem-
onstrated that imatinib dosed for a planned duration of 1 year
can prolong RFS in localised GISTs having a diameter  3 cm
with a macroscopically complete resection [17]. Therefore, adju-
vant therapy with imatinib for 3 years is the standard treatment
for patients with a significant risk of relapse [I, A]. A shared
decision-making process is needed when the risk is intermediate
[18]. Randomised clinical studies are ongoing to test longer dura-
tions of adjuvant therapy in GISTs.
The benefit associated of adjuvant imatinib may vary according
to the type of KIT/PDGFRA mutation, being greater in patients
with KIT exon 11 deletion mutations [19, 20]. Mutational analy-
sis is critical to make a clinical decision about adjuvant therapy.
There is a consensus that PDGFRAD842V-mutated GISTs should
not be treated with any adjuvant therapy, given the lack of sensi-
tivity of this genotype both in vitro and in vivo [IV, D]. Given the
data supporting the use of a higher dose of imatinib (800 mg
daily) in the case of an exon 9 KIT mutation in advanced GIST,
some expert clinicians prefer to use this dose even in the adjuvant
setting for this genotype [II, B] [21–23]. Regulatory constraints
may limit this practice, which is currently not supported in the
adjuvant setting by controlled trials.
With regard to so calledKIT/PDGFRA/BRAFWT GIST, there is a
consensus on avoiding adjuvant treatment in NF1-related and SDH
expression-negative GISTs [IV, D]. This reflects their lack of sensi-
tivity to imatinib and other approved tyrosine kinase inhibitors
(TKIs) in the advanced setting, as well as their peculiar natural his-
tory, which is often more indolent. Subgroup analyses of available
randomised trials are, however, too limited to provide sufficient evi-
dence. European and international cooperation would be vital to
determine best practices in the exceedingly rare paediatric GIST.
In case of tumour rupture at the time of surgery, there is spillage
of tumour cells into the peritoneal cavity; therefore, occult perito-
neal disease can be assumed to exist. This puts the patient at a very
high risk of peritoneal relapse [24]. Therefore, these patients
should be considered for imatinib therapy [IV, A]. The optimal
duration of treatment in these cases is unknown, given the uncer-
tainty whether these cells should be considered as metastatic.
If R0 surgery is not feasible, or it could be achieved through less
mutilating/function-sparing surgery in the case of volumetric
reduction (this includes total gastrectomy and all other major
procedures), pre-treatment with imatinib is standard [III, A]
[25, 26]. This may also be the case if the surgeon believes that the
surgical resection is safer after cytoreduction (e.g. the risk of
bleeding and tumour rupture is decreased). A shortcoming may
be the lack of reliable mitotic counting for accurate risk stratifica-
tion for adjuvant postoperative therapy. A biopsy with histologi-
cal and mutational analyses is recommended to confirm the
histological diagnosis, to exclude resistant genotypes to therapy
with imatinib (e.g. PDGFRA D842V mutations) and to propose
the 800 mg imatinib dose for less sensitive KIT exon 9 mutations.
Following maximal tumour response, generally after 6–
12 months, surgery is carried out. Early tumour response assess-
ment is required to avoid delaying surgery in the case of non-
responding disease. Functional imaging makes it possible to
assess the tumour response very rapidly, within a few weeks, par-
ticularly in the absence of mutational analysis. There are limited
data to guide the physician on when to stop imatinib treatment
before surgery; however, it can be safely stopped a few days or
even one day before surgery and can be resumed promptly when
the patient recovers from surgery.
Management of advanced/metastatic
disease (see Figure 2)
Imatinib is the standard treatment for locally advanced inoperable
and metastatic disease [I, A] [27–30], as well as for patients previ-
ously treated with adjuvant imatinib who did not relapse while
receiving it. Imatinib is also the standard treatment for patients
with metastatic disease who have had all lesions removed surgi-
cally, although surgery is not recommended as a primary
approach in the metastatic setting. The standard dose of imatinib
is 400 mg daily [I, A]. However, data have shown that patients
with tumours harbouring the KIT exon 9 mutation have signifi-
cantly better progression-free survival (PFS) on a higher dose
level, i.e. 800 mg daily, which is therefore held as standard treat-
ment in this subgroup [III, B] [31]. Patients with a PDGFRA
D842V mutation are generally insensitive to imatinib [32] and
other TKIs and are, therefore, candidates for clinical studies on
new agents targeting this mutation. It is doubtful whether patients
with so-called WT SDH-deficient GIST benefit from available
TKIs, though there are reports of activity of sunitinib [33].
In the metastatic setting, treatment with imatinib should be
continued indefinitely, since treatment interruption is generally
followed by relatively rapid tumour progression, even when
lesions have been previously surgically excised [I, A] [34]. When
treatment is started, the patient should be alerted to the impor-
tance of compliance with therapy, as well as interactions with
concomitant medications and foods, and the best ways to handle
side effects. Dose intensity should be maintained by proper man-
agement of side effects, and a correct policy of dose reductions
and interruptions should be applied in the case of excessive, per-
sistent toxicity. Retrospective data suggest that suboptimal
plasma levels of imatinib are associated with a worse outcome,
although a correlation with the outcome has never been estab-
lished prospectively [35]. Aside from its potential use to tailor the
imatinib dose, assessment of plasma level may be useful in the
case of: (i) patients receiving concomitant medications that put
them at a risk of major interactions or patients with previous sur-
gical resections able to decrease plasma levels; (ii) unexpected
observed toxicities; and (iii) progression on 400 mg, to rationally
lead the physician to increase the dose to 800 mg daily.
Close monitoring of the tumour response should be carried
out in the early phases of treatment. Follow-up should be contin-
ued throughout the treatment, since the risk of secondary pro-
gression persists over time. Complete excision of residual
metastatic disease has been shown to be associated with a good
prognosis, provided the patient is responding to imatinib, but it
has never been demonstrated prospectively whether this is due to
surgery or to patient selection [36–39]. Randomised trials did not
Clinical Practice Guidelines Annals of Oncology
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prove feasible (stopped early because of slow accrual), except for
a small positive trial in which all patients had peritoneal disease
[40]. Thus, the surgical option should be individualised after
making the decision with the patient in the case of uncertainty
[III, C]. Surgical excision of progressing disease has not been ben-
eficial in published retrospective series, but surgery of limited
progression, such as the ‘nodule within a mass’, has been associ-
ated with a PFS in the same range as for second-line treatment
with sunitinib. Therefore, this may be a palliative option for an
individual patient with limited progression, while continuing
imatinib [IV, C]. Non-surgical procedures (e.g. local treatment,
such as ablations or palliative radiotherapy) may be selected. In
the case of tumour progression on 400 mg, an option may be to
increase the imatinib dose to 800 mg daily [III, B], with the excep-
tion of insensitive mutations (if treated with the lower dose) [27–
30]. Dose escalation is particularly useful in the case of a KIT
exon 9 mutated GIST (if a higher dose was not selected from the
beginning), possibly in the case of changes in drug pharmacoki-
netics over time, or in the case of some molecular secondary alter-
ations. False progression on imaging should be ruled out due to
the response patterns (see below). Also, patient non-compliance
should be ruled out as a possible cause of tumour progression, as
well as drug interactions with concomitant medications.
In the case of confirmed progression or rare intolerance on
imatinib (after attempts to manage side effects through expert
advice, exploiting dose reductions and possibly plasma level
assessment), standard second-line treatment is another TKI,
sunitinib [I, A] [41]. The drug was proved effective in terms of
PFS following a ‘4 weeks on/2 weeks off’ regimen. Data have
shown that a continuously dosed daily oral regimen with a lower
daily dose (37.5 mg) is effective and well tolerated, although no
formal comparison has been carried out within a randomised
clinical trial [42]. This schedule could therefore be considered an
option on an individualised basis [III, C].
After confirmed progression on sunitinib, a prospective
placebo-controlled randomised trial proved that regorafenib, at
the dose of 160 mg daily for 3 out of every 4 weeks, can signi-
ficantly prolong PFS. This therapy, as it becomes routinely avail-
able, is therefore standard third-line therapy for patients
progressing on or failing to respond to imatinib and sunitinib [I,
A] [43].
Patients with a metastatic GIST should be considered for par-
ticipation in clinical trials of new therapies or combinations.
There is controlled evidence that patients who have already pro-
gressed on imatinib may benefit when re-challenged with the
same drug [44]. Likewise, there is evidence that continuing a
treatment with a TKI, even in the case of progressive disease, may
slow down progression as opposed to stopping it (if no other
option is available at the time), at least in a proportion of patients
with a slow progression. Therefore, re-challenge or continuation
of treatment beyond progression with imatinib to which the
patient has already been exposed is an option [II, B]. On the other
hand, the use of combinations of TKIs outside of clinical studies
should be discouraged, because of the potential for considerable
toxicity. Several TKIs have been tested in uncontrolled phase II
trials in imatinib-resistant patients, with observations of activity
in only a fraction of total patients.
Response evaluation
Response evaluation is complex, and early progression, in partic-
ular, should be confirmed by an experienced team. Antitumour
activity translates into tumour shrinkage in most patients, but
some patients may show changes only in tumour density on CT
scan, or these changes may precede delayed tumour shrinkage.
These changes in tumour radiological appearance should be con-
sidered as the tumour response. Even an increase in the tumour
size may be indicative of the tumour response if the tumour den-
sity on CT scan is decreased [45]. The ‘appearance’ of new lesions
could also be due to the easier detection of less dense tumours.
Therefore, both tumour size and tumour density on CT scan, or
consistent changes in MRI or contrast-enhanced ultrasound,
should be considered as criteria for tumour response. An FDG-
PET scan has proven to be highly sensitive in early assessment of
tumour response and may be useful in cases where there is doubt,
or when early prediction of the response is particularly useful
(e.g. preoperative cytoreductive treatments) [46]. However, a
small proportion of GISTs have no FDG uptake. The absence of
tumour progression after 6 months of treatment is also consid-
ered as tumour response [47]. On the other hand, tumour pro-
gression may not be accompanied by changes in the tumour size.
In fact, some increase in the tumour density within tumour
lesions may be indicative of tumour progression. A typical pro-
gression pattern is the ‘nodule within the mass’, by which a por-
tion of a responding lesion becomes hyperdense [48].
Follow-up
There are no published data to indicate the optimal routine
follow-up policy of surgically treated patients with localised dis-
ease. Relapses occur more often to the liver and/or peritoneum
(other sites of metastases, including bone lesions and other sites,
may be less rare along the course of metastatic disease treated
with several lines of therapy). The mitotic rate likely affects the
speed at which relapses take place. Risk assessment based on the
mitotic count, tumour size and tumour site may be useful in
choosing the routine follow-up policy. High-risk patients gener-
ally have a relapse within 1–3 years from the end of adjuvant ther-
apy. Low-risk patients may have a relapse later, although this is
much less likely. Routine follow-up schedules differ across
institutions.
The optimal follow-up schedules are not known. As an exam-
ple, in some institutions, high-risk patients undergo a routine
follow-up with an abdominal CT scan or MRI every 3–6 months
for 3 years during adjuvant therapy (with a tighter clinical follow-
up due to the need to manage the side effects of adjuvant ther-
apy), unless contraindicated, then on cessation of adjuvant ther-
apy every 3 months for 2 years, then every 6 months until 5 years
from stopping adjuvant therapy, and annually for an additional
5 years.
For low-risk tumours, the usefulness of a routine follow-up is
not known; if selected, this may be carried out with abdominal
CT scan or MRI, e.g. every 6–12 months for 5 years.
Very low-risk GISTs probably do not require routine follow-
up, although the risk is not zero. X-ray exposure is a factor to
Clinical Practice Guidelines Annals of Oncology
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consider, especially in low-risk GIST, with abdominal MRI being
an alternative [49].
Methodology
These Clinical Practice Guidelines have been produced by ESMO in
partnership with EURACAN, the European Reference Network for
rare adult solid cancers. These Clinical Practice Guidelines were
developed in accordance with the ESMO standard operating proce-
dures for Clinical Practice Guidelines development (http://www.
esmo.org/Guidelines/ESMO-Guidelines-Methodology). They are
conceived to provide the standard approach to diagnosis, treatment
and survivorship on sarcomas and GISTs. Recommended interven-
tions are intended to correspond to the ‘standard’ approaches,
according to current consensus among the European multidiscipli-
nary sarcoma community of experts. These are represented by the
members of the ESMO Sarcoma Faculty and experts appointed by
all institutions belonging to the Sarcoma domain of EURACAN.
Experimental interventions considered to be beneficial are labelled
as ‘investigational’. Other non-standard approaches may be
proposed to the single patient as ‘options’ for a shared patient-
physician decision in conditions of uncertainty, as long as some
supporting evidence (though not conclusive) is available.
Algorithms accompany the text, covering the main typical presenta-
tions of disease, and are meant to guide the user throughout the
text. The relevant literature has been selected by the expert authors.
A summary of recommendations is shown in Table 3. Levels of evi-
dence and grades of recommendation have been applied using the
system shown in Table 4. Statements without grading were consid-
ered justified standard clinical practice by the experts.
Disclosure
PGC has reported advisory roles for Deciphera Pharmaceuticals,
Eisai, Eli Lilly, Nektar Therapeutics, speaker’s honoraria from
Eisai, Eli Lilly, Pfizer, PharmaMar, and conducted studies spon-
sored by Amgen Dompe´, AROG Bayer, Blueprint Medicines,
Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline,
Novartis, Pfizer, PharmaMar; SBa has reported research support
from Novartis, Incyte, Blueprint Medicines, has received honoraria
Table 3. Summary of recommendations
Diagnosis and pathology/molecular biology
• Endoscopic ultrasound assessment and then follow-up is the standard approach for patients with oesophagogastric or duodenal nodules< 2 cm [IV, C]
• Biopsy/excision is the standard approach to tumours  2 cm in size [IV, C]
• Mutational analysis inclusion in the diagnostic work-up of all GISTs should be considered standard practice [II, A] (with the possible exclusion of < 2 cm
non-rectal GISTs)
Management of local/locoregional disease
• The standard treatment of localised GISTs is complete surgical excision of the lesion, with no dissection of clinically negative lymph nodes [III, A]
• If laparoscopic excision is planned, the technique needs to follow the principles of oncological surgery [III, A]
• When R0 surgery implies major functional sequelae, and preoperative medical treatment is not effective, the decision can be made with the patient to
accept possible R1 resection [IV, B]
• Adjuvant therapy with imatinib for 3 years is the standard treatment of patients with a signiﬁcant risk of relapse [I, A]
• PDGFRA D842V-mutated GISTs should not be treated with adjuvant imatinib [IV, D]
• Adjuvant treatment should be avoided in NF1-related and SDH expression-negative GISTs [IV, D]
• Patients at a very high risk of peritoneal relapse (in case of tumour rupture at the time of surgery) should be considered for imatinib therapy [IV, A]
• If R0 surgery with no expected major sequelae is not feasible, pre-treatment with imatinib is standard [III, A]
Management of advanced/metastatic disease
• Imatinib is the standard treatment of locally advanced inoperable and metastatic disease [I, A]
• Imatinib is also the standard treatment for patients with metastatic disease who have had all lesions removed surgically, although surgery is not recom-
mended as a primary approach in the metastatic setting. The standard dose of imatinib is 400 mg daily [I, A]
• Standard treatment of patients with KIT exon 9 mutation is 800 mg daily of imatinib [III, B]
• In the metastatic setting, treatment with imatinib should be continued indeﬁnitely, unless intolerance or speciﬁc patient request to interrupt [I, A]
• Surgery of residual metastatic disease should be individualised after making the decision with the patient in the case of uncertainty [III, C]
• Surgical excision of progressing disease should be considered for an individual patient with limited progression, while continuing imatinib [IV, C]
• In the case of tumour progression on 400 mg of imatinib, the dose can be increased to 800 mg daily [III, B] (with the exception of insensitive mutations)
• In the case of conﬁrmed progression or rare intolerance on imatinib, standard second-line treatment is sunitinib [I, A]
• Regorafenib, at the dose of 160 mg daily for 3 out of every 4 weeks, is the standard third-line therapy for patients progressing on or failing to respond to
imatinib and sunitinib [I, A]
• Rechallenge or continuation of treatment beyond progression with imatinib to which the patient has already been exposed is an option [II, B]
GIST, gastrointestinal stromal tumour; NF1, neuroﬁbromatosis type 1; PDGFRA, platelet-derived growth factor alpha; R0, no residual tumour; R1, microscopic
residual tumour; SDH, succinate dehydrogenase.
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or consultation fees from Novartis, Lilly, Pfizer, PharmaMar and
Bayer; SBi has reported advisory/consultant roles for Lilly, Bayer,
Pfizer, Novartis, Isolfol and Clinigen and conducted studies
sponsored by Janssen-Cilag, Eisai and Loxo Oncology; SBo has
reported honoraria and travel grants from Nanobiotix and Lilly
and received travel grants from PharmaMar; IB has received
research funds from Bristol-Myers Squibb, Merck Sharp &
Dohme, Novartis, Roche, Amgen and has reported advisory roles
for AstraZeneca, Roche, Merck Sharp & Dohme, LEO Pharma,
Amgen, Bristol-Myers Squibb, Pfizer and Novartis; TB has
reported honoraria from Roche and PharmaMar and advisory
board and honoraria from Amgen, Bayer, Novartis, Eisai and Eli
Lilly; JMB has reported consulting advisory role for PharmaMar,
Lilly, Bayer, Novartis and being a member of the speaker’s bureau
for PharmaMar and received travel grants from PharmaMar and
Lilly; APDT is a member of the speakers’ bureau for Lilly, Pfizer
and Merck Sharp & Dohme; XGDM has reported advisory role
for Lilly, PharmaMar and Novartis; PD has reported conducted
research sponsored by Eli Lilly; ME has participated in advisory
boards for Bayer, Sobi, Lilly, Eisai and Novartis; AMF has con-
ducted studies sponsored by Amgen Dompe´, AROG Bayer,
Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme,
GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SG has received
research grants and honoraria from Novartis, Pfizer and Bayer;
HG has received research grants from Novartis, Daiichi Sankyo
Pharma and Pfizer; HG has received research grants from
Novartis, Daiichi Sankyo Pharma and Pfizer; AG has reported
compensation for advisory boards from Novartis, Pfizer, Bayer,
Lilly, PharmaMar and Nanobiotix, honoraria from Novartis,
Lilly, PharmaMar and Nanobiotix, and research funds from
PharmaMar and travel grants from PhramaMar and Nanobiotix;
BH has received research grants from EuroSarc and has con-
ducted research with EIT Health in collaboration with GE health-
care and Philips, he has received reagents from Takeda and
Astellas to conduct clinical trials without direct funding; PH has
reported conducting research sponsored by Novartis, Blueprint
Medicines, Nanobiotix and Lilly and has received honoraria and
travel grants from PharmaMar, Eisai and Lilly; HJ has reported
co-appointment with Orion Pharma and holds stock in Sartar
Therapeutics, Faron Pharmaceuticals and Orion Pharma; RLJ is a
consultant for Adaptimmune, Blueprint Medicines, Clinigen,
Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Lilly, Merck
and PharmaMar; IJ has received honoraria from Lilly for lectures;
PJ has reported being a consultant for Stryker for the design of a
new tumour prosthesis; BK has reported honoraria from
Novartis, Pfizer and Bayer and advisory role for Bayer; KK has
received travel grants from Novartis and Pfizer; ALC has received
honoraria from Pfizer, Novartis, Lilly, Amgen, Bayer and
PharmaMar; MAP has served on advisory boards for Bayer and
Pfizer, and has received research grants from Novartis; PRe has
served on advisory boards for Novartis, Pfizer, PharmaMar,
Ariad, Merck, Deciphera, Roche, Clinigen and Lilly and has
received honoraria from Novartis, Pfizer, Bayer, PharmaMar and
Lilly; PRu has received honoraria for lectures from Novartis,
Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche and
has served as a member of advisory board for Novartis, Amgen,
Merck Sharp & Dohme, Bristol-Myers Squibb, Blueprint
Medicines; PS has received honoraria from Daiichi Sankyo
Pharma, Eisai, Eli Lilly, Medspace, Novaris, Swedish Orphan
Biovitrium, has reported consulting or advising roles for Sixth
Element Capital, Adaptaimmune, Amcure, AstraZeneca, Bayer,
Blueprint Medicines, Bristol-Myers Squibb, Boeringer
Ingelheim, Cristal Therapeutics, Daiichi Sankyo Pharma, Eisai,
Eli Lilly, Epizyme, Genzyme, Ipsen, Loxo Oncology, Medspace,
Nektar, Novartis, Philogen, Piqur Therapeutics, Plexxikon, is a
member of speaker’s bureau of Bayer, Eisai, Eli Lilly,
GlaxoSmithKline, Novartis, PharmaMar, Swedish Orphan
Biovitrium, has received research grants from Bayer, Blueprint
Medicines, CoBioRes, Exelixis, Bristol-Myers Squibb, Novartis,
Plexxikon, and has received travel grants from Sixth Element
Capital, Adaptaimmune, Amcure, AstraZeneca, Bayer, Blueprint
Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Cristal
Table 4. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service
Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses
of well-conducted randomised trials without heterogeneity
II Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials
or of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efﬁcacy with a substantial clinical beneﬁt, strongly recommended
B Strong or moderate evidence for efﬁcacy but with a limited clinical beneﬁt, generally recommended
C Insufﬁcient evidence for efﬁcacy or beneﬁt does not outweigh the risk or the disadvantages (adverse events, costs, . . .), optional
D Moderate evidence against efﬁcacy or for adverse outcome, generally not recommended
E Strong evidence against efﬁcacy or for adverse outcome, never recommended
aBy permission of the Infectious Diseases Society of America [50].
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Therapeutics, Daichii Sankyo Pharma, Eisai, Eli Lilly, Epizyme,
Genzyme, GlaxoSmithKline, Ipsen, Loxo Oncology, Medpace,
Nektar, Novartis, PharmaMar, Philogen, Piqur Therapeutics,
Plexxikon, Swedish Orphan Biovitrium; SSt has received honora-
ria from Eli Lilly and PharmaMar, research grants from Amgen
Dompe´, Advenchen, Bayer, Eli Lilly, Daiichi Sankyo Pharma,
Epizyme Inc., Novartis, Pfizer and PharmarMar; travel grants
from PharmaMar and has reported advisory/consultant roles for
Bayer, Eli Lilly, ImmuneDesign, Maxivax and PharmaMar;
WVdG has received research grants from Novartis; EW has
reported travel/research grants and/or honoraria from Novartis
Oncology, Milestone, Menarini, PharmaMar, Roche, Nanobiotix
and Bayer; JYB has declared research grants and honoraria from
Novartis, GlaxoSmithKline, Pfizer and Bayer; IL has received
honoraria from Bristol-Myers Squibb, MDS, Roche, Novartis
and Pfizer for scientific presentations or research; NA, RB,
JVMGB, AB, EDA, AFed, VF, AFer, GG, TG, RLH, RI, SK, DAK,
RP, PP, SP-N, ALP, OM, MM, MHR, AAS, SSl, KSH, MU, JW
and FVC have declared no conflict of interest. SF, AH and OZ
have not reported any potential conflicts of interest.
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